These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11287787)

  • 1. No correlation between aggression and platelet (3)H-paroxetine binding in obsessive-compulsive disorder patients.
    Marazziti D; Conti L; Pfanner C; Presta S; Rossi A; Gemignani A; Dell'Osso L; Cassano GB
    Neuropsychobiology; 2001; 43(3):117-22. PubMed ID: 11287787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased platelet 3H-paroxetine binding in obsessive-compulsive patients.
    Marazziti D; Rossi A; Gemignani A; Giannaccini G; Pfanner C; Milanfranchi A; Presta S; Lucacchini A; Cassano GB
    Neuropsychobiology; 1996; 34(4):184-7. PubMed ID: 9121618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased lymphocyte 3H-paroxetine binding in obsessive-compulsive disorder.
    Marazziti D; Baroni S; Masala I; Giannaccini G; Mungai F; Di Nasso E; Cassano GB
    Neuropsychobiology; 2003; 47(3):128-30. PubMed ID: 12759554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet serotonergic markers as endophenotypes for obsessive-compulsive disorder.
    Delorme R; Betancur C; Callebert J; Chabane N; Laplanche JL; Mouren-Simeoni MC; Launay JM; Leboyer M
    Neuropsychopharmacology; 2005 Aug; 30(8):1539-47. PubMed ID: 15886722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impulsive aggression in personality disorder correlates with tritiated paroxetine binding in the platelet.
    Coccaro EF; Kavoussi RJ; Sheline YI; Lish JD; Csernansky JG
    Arch Gen Psychiatry; 1996 Jun; 53(6):531-6. PubMed ID: 8639036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet serotonergic predictors of clinical improvement in obsessive compulsive disorder.
    Delorme R; Chabane N; Callebert J; Falissard B; Mouren-Siméoni MC; Rouillon F; Launay JM; Leboyer M
    J Clin Psychopharmacol; 2004 Feb; 24(1):18-23. PubMed ID: 14709942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet [3H]paroxetine binding in patients with OCD-related disorders.
    Marazziti D; Dell'Osso L; Presta S; Pfanner C; Rossi A; Masala I; Baroni S; Giannaccini G; Lucacchini A; Cassano GB
    Psychiatry Res; 1999 Dec; 89(3):223-8. PubMed ID: 10708268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet serotonin transporter in children and adolescents with obsessive-compulsive disorder or Tourette's syndrome.
    Sallee FR; Richman H; Beach K; Sethuraman G; Nesbitt L
    J Am Acad Child Adolesc Psychiatry; 1996 Dec; 35(12):1647-56. PubMed ID: 8973072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet paroxetine binding in major depressive disorder with and without comorbid obsessive-compulsive disorder.
    Nelson EC; Sheline YI; Bardgett ME; Jackson JL; Csernansky JG
    Psychiatry Res; 1995 Sep; 58(2):117-25. PubMed ID: 8570763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet monoamine oxidase activity in obsessive-compulsive disorder.
    Arrojo M; Baca-Garcia E; Perez-Rodriguez MM; Dolengevich-Segal H; Navio-Acosta M; Rodriguez-Salgado B; Saiz-Ruiz J
    Eur Psychiatry; 2007 Nov; 22(8):525-9. PubMed ID: 17761404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteration of the platelet serotonin transporter in romantic love.
    Marazziti D; Akiskal HS; Rossi A; Cassano GB
    Psychol Med; 1999 May; 29(3):741-5. PubMed ID: 10405096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?
    Geller DA; Biederman J; Stewart SE; Mullin B; Farrell C; Wagner KD; Emslie G; Carpenter D
    J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S19-29. PubMed ID: 12880497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease in thalamic volumes of pediatric patients with obsessive-compulsive disorder who are taking paroxetine.
    Gilbert AR; Moore GJ; Keshavan MS; Paulson LA; Narula V; Mac Master FP; Stewart CM; Rosenberg DR
    Arch Gen Psychiatry; 2000 May; 57(5):449-56. PubMed ID: 10807485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychopathology and personality characteristics in relation to blood serotonin in Tourette's syndrome and obsessive-compulsive disorder.
    Cath DC; Spinhoven P; Landman AD; van Kempen GM
    J Psychopharmacol; 2001 Jun; 15(2):111-9. PubMed ID: 11448084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive behaviour and platelet 3H-paroxetine binding in schizophrenia.
    Maguire K; Cheung P; Crowley K; Norman T; Schweitzer I; Burrows G
    Schizophr Res; 1997 Jan; 23(1):61-7. PubMed ID: 9050129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paroxetine treatment of compulsive hoarding.
    Saxena S; Brody AL; Maidment KM; Baxter LR
    J Psychiatr Res; 2007 Sep; 41(6):481-7. PubMed ID: 16790250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse relationship between numbers of 5-HT transporter binding sites and life history of aggression and intermittent explosive disorder.
    Coccaro EF; Lee R; Kavoussi RJ
    J Psychiatr Res; 2010 Feb; 44(3):137-42. PubMed ID: 19767013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder.
    Rosenberg DR; Stewart CM; Fitzgerald KD; Tawile V; Carroll E
    J Am Acad Child Adolesc Psychiatry; 1999 Sep; 38(9):1180-5. PubMed ID: 10504818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of acute serotonin challenge on executive planning in patients with obsessive-compulsive disorder (OCD), their first-degree relatives, and healthy controls.
    Lochner C; Chamberlain SR; Kidd M; Taljaard L; Fineberg NA; Robbins TW; Stein DJ
    Psychopharmacology (Berl); 2020 Oct; 237(10):3117-3123. PubMed ID: 32638035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.